Efficient treatment of experimental cerebral malaria by an artemisone-SMEDDS system: impact of application route and dosing frequency

Johanna Zech \textsuperscript{a}, Nadeen Salaymeh \textsuperscript{b}, Nicholas H. Hunt \textsuperscript{c}, Karsten Mäder \textsuperscript{a}\textsuperscript{*#}, Jacob Golenser \textsuperscript{b}\textsuperscript{*#}

\textsuperscript{a} Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Strasse 3, 06120 Halle (Saale), Germany, e-mail: karsten.maeder@pharmazie.uni-halle.de

\textsuperscript{b} Department of Microbiology and Molecular Genetics, The Kuvn Centre for the Study of Infectious and Tropical Diseases, The Hebrew University of Jerusalem, Jerusalem 9112002, Israel

\textsuperscript{c} Discipline of Pathology, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia

\textsuperscript{*} Equal contribution

\textsuperscript{#} Corresponding authors
Abstract

Artemisone (ART) has been successfully tested in vitro and in animal models against several diseases. However, its poor aqueous solubility and limited chemical stability are serious challenges. We developed a self-microemulsifying drug delivery system (SMEDDS) that overcomes these limitations. Here, we demonstrate the efficacy of this formulation against experimental cerebral malaria in mice and the impact of its administration using different routes (gavage, intranasal delivery and parenteral injections) and frequency on the efficacy of the treatment. The minimal effective oral dose was 20 mg/kg. We found that splitting a dose of 20 mg/kg ART given every 24 hours, by administering two doses of 10 mg/kg each every 12 hours, was highly effective and gave far superior results compared to 20 mg/kg once daily. We obtained the best results with nasal treatment, oral treatment was ranked second and the least effective route of administration was intraperitoneal injection. A complete cure of experimental cerebral malaria could be achieved through choosing the optimal route of application, dose and dosing interval. Altogether, the developed formulation combines easy manufacturing with high stability, and is a successful and very versatile carrier for the delivery of ART in treatment of human severe malaria.
Keywords: artemisone, malaria, SMEDDS, microemulsion, drug delivery, self-emulsifying, oral, nasal, intraperitoneal

Introduction

Artemisinin derivatives are first-line anti-malarial drugs (1). However, resistance to all commercial artemisinins, including their combinations with other anti-plasmodial drugs, has been reported (2, 3). Artemisone [ART], a relatively new artemisinin derivative (4), was previously examined for plasmodial growth inhibition in vitro (5) and in mouse models of malaria and proved superior to commercially available artemisinin derivatives. ART has higher activity in vivo and in vitro compared to artesunate, it is not metabolized to the neurotoxic dihydroartemisinin, unlike the other artemisinins, and is not exposed to severe first pass metabolism (6). Consequently, it has a longer t1/2 in vivo and is about 3-5 times more active than artesunate, in vitro and in vivo (4, 7). ART toxicity has not been extensively evaluated in vivo but we have not seen any immediate effects after using our formulation in the current and previous experiments (8). In vitro studies revealed a decreased toxicity compared to artesunate (9). Resistant plasmodia are more sensitive to ART than the currently used artemisinins (10–12).

In vivo, ART has been injected after solubilization in dimethylsulfoxide (DMSO) (because of its poor aqueous solubility) (7) or inserted subcutaneously in solid or pasty polymers for slow release (13, 14) thereby necessitating a chirurgic intervention. Recently, we developed a new formulation for ART that overcomes the limitation of the lipophilic drug by dissolution in a self-microemulsifying drug delivery system [SMEDDS] / microemulsion [ME] (15). Its delivery is simple and may overcome problems related to...
compliance. Oral administration of this formulation by gavage has been found very efficient in mice infected with *Schistosoma mansoni* (15).

It has been speculated that artemisinins are active against both schistosomes and plasmodia through the heme-initiated formation of free radicals (16). Consequently, it is the goal of this study to evaluate the efficacy of the ART-SMEDDS/ME formulation in a mouse model of cerebral malaria. We aimed to explore the impact of different administration routes (oral gavage, intranasal delivery or parenteral injections) and frequency on the efficacy of the treatment.

The choice of an appropriate delivery system is crucial for the efficacy of treatment with any drug. ART is a Biopharmaceutical Classification System (BCS) class II drug with high permeability and low solubility (Mw = 401.5 g/mol, aqueous solubility = 89 mg/L, Log P = 2.49) (6). For oral administration, a suitable delivery system must increase dissolution kinetics to enhance bioavailability (17). Likewise, Steyn et al. report that absorption of dissolved ART from their “Pheroid™” delivery system in a mouse is almost five-fold higher than from a drug suspension (18). Furthermore, for the treatment of schistosomiasis in mice, we found that 40 mg/kg per dose was sufficient if ART was dissolved in our SMEDDS (15), while to obtain similar results with a suspension required 400 mg/kg of the drug (19).

A variety of complex delivery systems have been proposed for a broad range of routes of administration to overcome the low solubility and relatively poor stability of ART in an aqueous environment (Table 1).
Most of the methods that are presented (Table 1) were not examined for their biological activity or were determined only in vitro. A few successful methods that were examined in mice are associated with a surgical procedure. The relevance of murine models to human malaria has been extensively studied, and confirmed (28–30).

Most importantly, effective therapy does not only depend on a formulation suitable for the drug but must also assure applicability under the conditions in which treatment is delivered. Today, malaria is particularly prevalent in remote, rural areas where adequate health care may be hard to access. Hence, pre-referral treatment can be vital for patient survival as rapid progression and deterioration are common in cases of severe malaria (31). While for children under the age of six the WHO recommends the use of rectal artemesunate, only parenteral administration is available for other age groups as pre-referral medication (32, 33). Here an oral or – in the case of coma or vomiting – intranasal formulation, easily administered without special skills or injection or infusion equipment, could provide immediate first access to antimalarial treatment. Additionally, storage stability and cost of production of such a drug delivery system have to be considered to make it applicable in the poorly-resourced regions where malaria is most common.

In addition to poor and variable absorption after oral administration, chemical stability is a challenge for ART and other artemisinins. Exposure to buffer solutions causes a degradation of 25% (pH 7.4) or 80% (pH 5) within one month (24). With the exception
of our SMEDDS, all oral ART formulations tested in vivo that have been published are aqueous dispersions. Unfortunately, no stability data have been reported for these formulations. With the water-free SMEDDS, and even with a ME formed from SMEDDS and 50% water, we achieved good ART stability even at high ambient temperatures (at least 3 months, 30°C) (15).

Based on these considerations, we examined in an animal model our ART SMEDDS/ME formulation as a potential simple, first-response drug delivery system for severe or cerebral malaria. Microemulsions are thermodynamically stable, isotropic systems usually comprised of an oil/lipophilic component, surfactant, co-surfactant and an aqueous phase with possibly a co-solvent (34, 35). If formulated as a water-free pre-concentrate, they are classed as SMEDDS, which spontaneously form a ME when brought into contact with aqueous liquids, e.g. with the gastric or intestinal fluids. Liquid SMEDDS can be produced by simple mixing. Advantages include cheap manufacturing, desirable storage stability, different routes of application and facile administration (36). They are thermodynamically stable and avoid – in contrast to thermodynamically unstable dispersions (e.g. emulsions, suspensions, liposomes) – the need to control the particle size.

Consistent and fast drug absorption, usually reaching $C_{\text{max}}$ in less than a few hours, is observed for most drugs orally administered in SMEDDS/ME (37). Such pharmacokinetics are especially appropriate for ART because artemisinins are usually applied as fast-acting, first response drugs to rapidly reduce the parasite burden. Oral SMEDDS are already marketed for prescription drugs (38, 39). ME and SMEDDS have been proposed as delivery systems for other artemisinin derivatives (40–44), but, to our
knowledge, apart from our formulation no such system for ART has been developed so far.

In the case of cerebral malaria, the possibility of intranasal administration of ME, utilizing the proposed nose-to-brain transport system (45), could also facilitate direct targeting of plasmodia residing in the small vessels of the CNS. Efficacy of intranasal dihydroartemisinin and artesunate against cerebral malaria has already been shown in mice (46, 47).

Besides the drug delivery system, an appropriate dosing scheme is essential for adequate treatment. For artemisinin-based malaria therapy, the length of the interval to reach a minimum parasiticidal drug concentration is crucial for efficacy (48, 49). Although this correlation has sometimes been criticized as being oversimplified (50, 51), it has been proposed by pharmacokinetic modeling that the combined periods of exposure to parasiticidal concentrations of the drug can determine the success of treatment. Prolonged killing times could even help to overcome slow parasite clearance and partial artemisinin resistance emerging in Southeast Asia, caused by mutations in the PfKelch13 propeller domain of P. falciparum (48, 52–54). This probability is of extreme importance, as artemisinins and artemisinin-based combination therapies are still the WHO-recommended first-line treatment for uncomplicated as well as severe malaria (1). Increasing or even preserving the potential of the most effective class of antimalarial drugs available today by simple changes to dosing regimens seems particularly attractive because it avoids the high risks and costs of developing new compounds and can be put into clinical practice within a short time with moderate development costs.
Based on the aspects mentioned above, and encouraged by the successful treatment of experimental schistosomiasis with the ART SMEDDS/ME (9), we evaluated the effect of this formulation on experimental cerebral malaria in mice. In particular, we studied those parameters that could give insight into the pharmacokinetics of the system. Curative experiments were compared with drug serum levels and further investigated the impact of routes of administration (oral, intranasal or parenteral) and dosing intervals on the therapeutic outcome.

Results and discussion

Drug Delivery System

The formulations used in this work were designed for both oral and intranasal administration by careful selection of the employed excipients. The low viscosity (10 mPas) of the SMEDDS-20 formulation (composed of 20 % w/w SMEDDS-100 and 80 % w/w PBS) is well suited for oral application via a thin gavage needle (20 gauge) and was therefore selected for administration via that route. SMEDDS-50 only comprises 50 % PBS and therefore is considerably more viscous (118 mPas) than SMEDDS-20. However, increased viscosity is expected to prolong the residence time in the nasal cavity (55). Furthermore, only small volumes can be applied nasally and a higher drug load is possible in SMEDDS-50 compared to SMEDDS-20 (15). Its neutral pH of around 6.5 is close to the pH in the nasal mucus (56), ensuring good tolerability, drug stability and a very moderate risk of precipitation of both drug and excipients at the ME-mucus interface.
The high concentration of surfactant and the surface activity of ME have given rise to the discussion and study of their local tolerability (56–59), e.g. for intranasal treatment. Diverse results were observed, depending on the nature and ratio of the excipients used, duration and frequency of exposure. Though long-term toxicity cannot be ruled out for our formulation, no specific immediate signs of discomfort were observed in the animals treated orally, intranasally or via i.p. injections.

**Hemolysis**

Drug-free SMEDDS-100 and SMEDDS-100 containing 5% w/w ART were tested for their capacity to cause hemolysis. The formulations were assayed in concentrations of up to 1 mg SMEDDS/ml final erythrocyte suspensions in PBS and had no hemolytic activity (measured hemolysis < 0.1%). To further confirm that neither high drug concentrations nor the high amount of the surfactant in the SMEDDS could cause hemolysis, 50 µg/ml ART (dissolved in DMSO) and 1 mg/ml Kolliphor HS15 also were examined individually. No hemolytic activity was found. Triton X 1% w/v in PBS (positive control) lysed all erythrocytes while no hemolysis was observed for physiological saline.

**In vivo experiments**

The mouse model used in the experiments results in the death of about 95% of the untreated C57Bl/6 mice from a pathology closely resembling cerebral malaria in humans (60). Deaths occurred on days 6-9 post inoculation (p.i.) with 5x10⁴ erythrocytes parasitized by *P. berghei* ANKA, in compliance with the protocol for the model (7). We observed impairment of the blood-brain barrier by penetration of Evan’s Blue into the brain parenchyma of infected mice and early death at relatively low parasitemia when mice were not anemic, equivalent to what has been described in (14). A close
observation of the same model revealed similar courses of parasitemia and mortality and activation of brain microglia and astrocytes as well as typical intra-cerebral hemorrhages (61).

Artemisone serum concentrations. Serum concentrations of ART were measured via LC-MS in serum collected from mice 2 and 8 hours after gavage of either 40 mg/kg ART in SMEDDS-20 or placebo (Table 2). As expected, no drug was found in the serum of the placebo-treated mice. After 8 hours, ART could still be detected in the serum samples of all three animals in that group but, in two of those mice, serum levels were below the lower limit of quantification of 180 ng/ml. ART at 900 – 2300 ng/ml was present after 2 hours, ten times the maximum concentration found in the first human tolerability studies (140.2 ng/ml) (4) and a thousand times higher than the in vitro EC₅₀ against *P. falciparum* (1 – 2 ng/ml), determined for our formulation or ART dissolved in DMSO (10, 15).

The high bioavailability of ART within 2 hours after dosing and its rapid elimination by 8 hours are in accordance with what is generally observed for a variety of drugs orally administered in ME and SMEDDS formulations, such as Neoral® and Norvir® (37–39, 62).

Based on a t½ of only 2.8 hours found in humans (4), the results suggest that after 2 hours ART uptake is mostly complete: for the average of 1.5 µg/ml ART found after 2 hours, about 0.34 µg/ml would remain at 8 hours if no more drug absorption occurs. The observed variations in serum concentrations can be attributed to the mice not being fasted before dosing. The feeding before or after gavage could affect the delivery of ART, either through pH, gastrointestinal motility and stomach passage times, digestive
enzymes or interaction with food components. We did not apply fasting before or after gavage because fasting by itself would affect the outcome of the disease (63).

Table 2

Prophylactic treatment.

The ED_{50} for *P. falciparum* of ART in our SMEDDS was found to be 1-2 ng/ml in vitro (15). Hence, it is reasonable to expect *in vivo* effects even at serum concentrations below the LLD of our LC-MS method (60 ng/ml). Therefore, we used prophylactic treatment, prior to parasite inoculation, as an *in vivo* bioassay to gain additional information on the pharmacokinetics of the formulations and their effects *in vivo*.

To rule out any antimalarial effect of the plain ME *in vivo*, mice were treated with drug-free formulations, via gavage or intranasally, once a day on days 3-5 p.i. All animals exhibited characteristic clinical signs and had to be sacrificed or died of cerebral malaria less than 24 hours before or after the untreated control mice.

Table 3

The parasitemia in all mice was below 15 %, confirming that the vehicle did not alter the course of the infection. Hence, there was no need to include additional placebo groups in further treatment studies.

Table 3
The prophylactic treatment with ART-loaded SMEDDS was performed in mice that were administered 40 mg/kg ART via gavage once, at a specific time point before inoculation of malaria-infected erythrocytes. Any changes in the course of the disease can thus be attributed to the amount of drug present at the time of inoculation. Treatment 2 or 8 hours before infection delayed the appearance of parasites in the bloodstream by 24-48 hours, and resulted in a shift of the disease from cerebral to anemic malaria in 3/5 and 2/4 animals, respectively (data not shown).

The experiment was repeated, including 0.5, 2 and 24 hours before infection, to cover a more comprehensive time range in which ART could be present in the serum (Fig 1).

Treatment 24 hours prior to inoculation led to drug concentrations that were too low to change the course of the infection when compared to the untreated control group, as all animals in both groups died of cerebral malaria on day 8 p.i. The appearance of parasites in the bloodstream was delayed by 48 hours if mice were given ART 0.5 or 2 hours before infection. A shift from cerebral to anemic malaria occurred in 3/5 and 1/4 mice, respectively. The difference between the number of days that death was delayed in the anemic mice, in the two experiments, is not statistically significant (t-test, p >0.05).

Nevertheless, more animals experienced a shift to anemic malaria if treated at time points closer to infection. For other small molecules in microemulsions, C_{max} was reached as soon as 30 – 60 min after gavage (64, 65). With similar kinetics for our experiment, the time during which the plasmodia are subjected to the minimum parasiticidal concentration (MPC) could be considerably longer for ART given only 30
min prior to infection. This prolonged “effective time” could, in consequence, lead to a greater reduction of the parasite load.

The serum ART concentrations and their resulting effects suggest a fast drug uptake into the blood within an hour after dosing, followed by a first-order, $t_\text{1/2}$-controlled elimination of ART. Overall, we conclude that enough drug remains after 8 hours for anti-plasmodial activity, but not after 24 hours.

Fig- 1

Dose-response: Dose-response was confirmed for orally administered ART in SMEDDS-20 in a mouse model of cerebral malaria. For *P. berghei* ANKA infection in mice, an ED$_{90}$ of 11.67 mg/kg has been described after oral administration of an aqueous ART suspension on days 0-3 p.i. (10). Considering the increased bioavailability of most small, lipophilic drugs if administered in a ME, we anticipated a more pronounced effect for our formulation.

Animals were therefore treated with 10, 20 or 40 mg/kg ART in SMEDDS-20 once a day on days 3-5 p.i. No signs of toxicity were observed, but mice treated with the 40 mg/kg dose appeared more alert and hyperactive during a short period after treatment. Clear dose dependence was found for the delay of parasite detection in the blood and for the survival of the animals. The 40 mg/kg dose delayed the appearance of detectable parasites in the peripheral blood by one week. While 10 mg/kg was not enough to shift the course of the infection from cerebral malaria to anemic malaria, such a shift occurred in mice that received 20 or 40 mg/kg, respectively (Figure 2). The combined results of
the two separate experiments indicates a dose-dependent pattern of response (Table 4); while no animals survived if administered 10 mg/kg, giving 20 and 40 mg/kg ART led to infection-free survival rates of 20 and 30 %, respectively. A shift from cerebral malaria to anemic malaria occurred in 4/10 animals in all the groups but was only observed in the second run for the 10 mg/kg dose. Such a shift would enable a thorough diagnosis and additional treatment to infected individuals. In view of the results, a daily dose of at least 20 mg/kg was used as the standard dose in further experiments.

The results imply that, similar to what has been described for artesunate in humans (66), there is a ceiling effect for ART if orally administered in the SMEDDS every 24 hours at around 20 mg/kg. This indicated that a decrease in dosing interval rather than a higher drug dose might increase the efficacy of the treatment.

![Fig- 2](http://aac.asm.org/)

Table 4

Chi-square test reveals an overall significant effect of the treatments (p=0.036). There is an increase in survival parallel to increasing ART dose and examination of the effects of combined AM and survival reveals increased significance (p= 0.013).

**Dosing interval.** The influence of treatment frequency on the efficacy of artemisinin-based combination therapies (ACTs) for malaria patients has frequently been debated in recent years (48, 52, 66–68). We found that splitting a dose of 20 mg/kg ART given...
every 24 hours into two doses of 10 mg/kg each, every 12 hours, dramatically improved the outcome. While all mice that received 20 mg/kg in 200 µl SMEDDS-20 once-daily died of anemic malaria, parasite-free survival was reached in all animals that were given a split dose of 10 mg/kg in 100 µl SMEDDS every 12 hours (Figure 3 and Table 5).

In general, two parameters are essential for choosing the right dosing interval in malaria treatment:

(a) The stage-specificity of the drug has to be considered in cases of infections that present synchronized cycles of parasite blood stages. The maximum efficacy of a drug can only be exploited if the stages most sensitive to the drug are present at the time it reaches concentrations above the MPC in the bloodstream (68, 69). The artemisinins are well known for their activity against very early ring stages of *P. falciparum* (69), though trophozoites and schizonts also have been reported to be sensitive (70, 71). However, artemisinins increasingly accumulate in parasitized erythrocytes in accordance with intracellular parasite development (72). In the *Plasmodium berghei* ANKA mouse model, parasites are not age-synchronized before infection and sensitive parasites are most likely always present, though their percentage might vary. In any event, the *Plasmodium berghei* ANKA - C57Bl/6 mouse combination is an appropriate model for human cerebral malaria (29).

(b) The amount of time during which drug serum concentrations above the MPC are maintained determines the outcome of the treatment. If a twice-daily, half-dose regime leads to an increase in combined killing time per day (compared to the once-daily administration of the total dose), the total number of killed or damaged parasites is obviously larger, as explained by Kay et al. (48). This could be the case if the
administered drug has a ceiling effect, something observed for artesunate (66) and for ART in our dose-dependence studies, where increasing the amount of ART from 20 to 40 mg/kg only slightly improved efficacy. Pharmacological modelling has predicted that by splitting the daily dose of artemisinins and doubling the treatment frequency, the killing time would almost be doubled, increasing parasite eradication and dramatically reducing treatment failure rates of *P. falciparum* infections in humans (48, 73). Unfortunately, in vivo studies in patients failed to support this theoretical calculation (66, 67, 74). Possible explanations for the differing results from these clinical studies – the influence of reduced ring-stage susceptibility due to resistance, as well as acquired immunity in the patients – have been discussed (68, 73). These factors are not relevant in our experimental system that uses naïve mice and a *Plasmodium berghei* ANKA strain that is not drug resistant. Rather, *Plasmodium berghei* ANKA infections in mice induce a fulminant lethal disease, similar to human severe and cerebral malaria in non-immune patients (60).

Many field studies use parasite clearance in the peripheral blood following treatment as the endpoint, a method that overlooks non-circulating parasites whilst considering dead but not yet cleared blood-stage plasmodia. When the number of patients succumbing to severe malaria is below 2 %, a reliable statistic based on mortality/parasite free survival is difficult (67, 73, 74). In our experiments in mice, 20 mg/kg ART every 24 h did not save most animals but could shift the disease from cerebral malaria towards anemia that killed the animals about a week after the death of the untreated animals. A similar delay in patients might be crucial in saving life by enabling proper diagnosis and treatment. However, the split dose delivered every 12 hours led to superior efficacy, with 100 % parasite-free survival. Caution is needed in comparing the results of treatment of people...
infected with malaria to laboratory results of treatment of experimental cerebral malaria:

the severity of human infections is not necessarily known and concomitant infections
with other infectious agents are common. The immune status also is not well defined,
especially towards malaria in endemic areas. The situations of resistance to artemisinins
and even drug consumption (anti-malarial and other drugs) are not defined. Obviously,
in our pre-clinical study we avoided these factors by using naïve mice and a drug-
sensitive *Plasmodium berghei* ANKA strain. In human clinical studies, when ACT was
used (66, 67, 74) the observed fast onset of parasite reduction was mainly due to the
artemisinin component, whereas the survival outcome might be a result of the drug
combination (73). Therefore, our experiments, with mice receiving only ART, specifically
show the effect of altering the dosing regimen of this agent in the absence of the actions
of other drugs.

Taken together, these factors could have contributed to our finding that the results of the
dosing interval study precisely confirm the predicted effect of the pharmacological
modelling, with a split dose of 10 mg/kg twice a day curing all mice in that treatment
group (Figure 3).

The prophylactic experiment (Fig 1) implies that 24 hours after administration of 20
mg/kg ART an insufficient concentration of the drug remains in the blood to kill the
injected parasites. In consequence, in the one dose per day treatment regime, there is a
time period during which no killing of parasites will occur. Considering that 8 hours after
drug delivery an effect of the drug was still found, it is possible that remaining drug
concentrations of a 10 mg/kg dose might be high enough to still affect parasite viability
until the administration of the next drug dose. This could be examined by further
prophylactic studies. Thus, increasing treatment frequency rather than elevating the administered dose may improve the outcome and also reduce $C_{max}$ and consequent drug-induced side effects and toxicity.

**Fig- 3**

**Table-5**

**Route of application.**

Three different routes of administration – oral, intranasal and parenteral – were compared by administering 20 mg/kg ART every 24 h on days 3-5 p.i. (Figure 4,
As a parenteral route, SMEDDS-20 was delivered via i.p. injections, a method that is more often applied to animals than to humans (46, 75).

Administration of ART i.p. delayed death but still led to cerebral malaria in 30% of the animals. After oral treatment, 90% of the mice showed a shift to anemic malaria with consequent prolonged survival, and in one mouse no parasites could be detected until the end of the experiment. Intranasal ART administration saved 50% of the mice and anemic malaria occurred in the other half. The efficacy can be rated as i.p. < oral < nasal administration and this order was confirmed by repeating the experiment (both experiments are summarized in Table 6).

The different outcomes for the studied routes of drug administration could possibly be explained by variations in:

(a) bioavailability
(b) the time of drug uptake and maintenance period of MPC
(c) the tissues/compartments that are reached by ART.

Injections via the i.p. route, similar to i.v. administration, lead to 100% bioavailability of the given drug, and we expect a high $C_{\text{max}}$ at a short $t_{\text{max}}$ (75). Consequently, neither a large total amount of available drug, nor exceptionally high serum concentrations, can be considered responsible for the more effective treatment provided by oral and intranasal dosing. Instead, they presumably are due to either prolonged drug uptake and consequently longer exposure of the parasite, or delivery of the drug to different compartments, e.g. the brain.
The effect of the extended killing time has already been discussed, with more hours/day above the MPC resulting in the elimination of more parasites. It is essential to consider the length of individual drug pulses, during which drug concentrations above the MPC are reached. Longer durations of individual treatments were more effective in decreasing the number of parasites that survive initial exposure to artemisinins (69), due to increased probability of exposure of parasite stages that are more sensitive to the drugs. A route of application for our SMEDDS that provides extended drug uptake could, therefore, considerably increase the effectiveness of ART. After oral administration, passage along the gastrointestinal tract and interaction with food components may lengthen the drug uptake. For intranasal dosing, two mechanisms have been shown to prolong the duration of drug delivery: the nasal mucosa can act as a drug reservoir, suggesting continued drug release even after clearance of the formulation from the nasal cavity (76). In addition, the high viscosity of the SMEDDS is likely to considerably increase the time of residency of the ME on the nasal mucosa (55). In C57BI/6 mice, a mucociliary transport of 1.3 mm/min would remove low-viscous aqueous solutions from the nasal cavity in less than 20 min (77), but a considerably longer time of residency and consequent drug uptake can be assumed for our formulation with a viscosity of 118 mPas (9). However, when considering serum concentration time-curves for other small-molecule drugs delivered intranasally in ME, no prolonged drug release was found when compared to typical plasma curves for oral administration (58, 59, 78, 79) but, rather, an exceptionally fast drug uptake (59, 79–83). For a mirtazapine ME, a higher \( C_{\text{max}} \) and AUC, but shorter \( t_{\text{max}} \) and \( t_{1/2} \) are reached if applied intranasally instead of orally (78).
Nasal administration has been studied as a method to directly target the brain via the uptake of the drug through the olfactory region of the nasal epithelium and branches of the trigeminal nerve (45). This “nose-to-brain transport” should be especially effective in rodents, considering their – compared to humans – large intranasal surface area, consisting of 50% olfactory epithelium (84). High drug concentrations in the brain following intranasal administration in ME have been reported for a variety of small-molecule drugs when compared to the i.v. or oral routes (78–80, 82, 85). There is evidence for intravascular accumulation of parasitized erythrocytes in brain vessels in the mouse model, and in human cerebral malaria (86). Consequently, targeting the brain would be an advantage and enhanced treatment of parasites in the brain is, therefore, a possible explanation for the efficacy of intranasal administration of ART. A different explanation could be an increase of the apparent plasma half-life of ART, with the cerebrospinal fluid and brain tissue forming a drug reservoir, protecting ART from rapid metabolism and slowly releasing it into the plasma. A prolonged brain half-life can be found for other lipophilic small-molecule drugs after oral delivery (87, 88). But as little is known about the metabolism and excretion of ART from the CNS this must remain speculative for now. For other artemisinin derivatives, prolonged brain- and plasma concentrations could not be observed after intranasal administration. However, those experiments used nano lipid carriers (89) and aqueous solutions (47). The latter have been found to be inferior in intranasal drug delivery when compared to ME (79, 80, 85, 90).

Despite the pronounced result of nasal delivery, often this method is not optimal for measuring biodistribution because the drug may reach various organs: the brain, the respiratory tract and the intestine (45, 91). In addition, frequent use of this route may
lead to mucosal damage. Therefore, we have focused on gavage and consequently could more accurately estimate the availability of the drug in the blood, which is the crucial factor in parasite elimination. However, faced with the challenge of treating a potentially unconscious or vomiting severe malaria patient, intranasal administration might be a beneficial instrument to possess. Thus, the intranasal route was of interest to us - and hence included in this study.

Overall, both prolonged delivery with consequently extended potential killing duration as well as delivery to the brain (for intranasal treatment), are to be considered as possible explanations for the increased efficacy of the oral and intranasal route in our experiments and for future applications.

Fig- 4

Table 6
Late treatment. Delayed treatment, on days 6-9 p.i. when mice were suffering from fulminant disease, was studied. Mice were treated every 12 hours, with 20 mg/kg drug intranasally or 40 mg/kg via gavage (Table 7). Parasitemia dropped in all mice, from 1-3% on day 6 p.i. to below the detection limit, within 48 hours after the beginning of treatment. In the animals that died of severe malaria, parasites were absent for at least 10 days post-treatment, with deaths occurring between day 21 and 24 p.i. The effective late treatment with a high parasite reduction rate is common for artemisinins (51) and the consequent time window before recurrence of the plasmodia can be critical in clinical cases. It would allow the rescue of already severely infected patients and subsequent treatment with other, longer-acting antimalarial drugs.

Table 7
Conclusion

Because complete cure of experimental cerebral malaria was achieved when using the optimal route of application, dose, and dosing interval, our formulation is altogether a promising, very versatile carrier for the delivery of ART in the treatment of severe or cerebral malaria.
Materials and methods

Artemisone (ART) was kindly donated by Cipla (Mumbai, India) and was used for the experimental procedures that are included in this paper. Artemisone that had been donated by Richard K. Haynes (The North-West University, Potchefstroom, South Africa) was previously used for the development of the ART formulation (15). Polysorb® ID 46 (Isosorbide caprylocaprate diester) was a gift of Roquette, (Lestrem, France). Capmul® MCM EP (Glycerol monocaprylocaprate) was obtained from Abitec (Columbus, USA). Kolliphor® HS15 (Polyoxyl (15) Hydroxystearate), supplied by BASF (Ludwigshafen, Germany), was melted and homogenized before use to ensure a homogenous composition. Propylene glycol and indomethacin were bought from Caesar & Lorentz GmbH (Hilden, Germany). All chemicals were of analytical grade. HPLC solvents were purchased as HPLC grade. Sterile filtered mouse serum was bought from Biowest (Nuaille, France). Phosphate buffered saline pH 7.4 (PBS) was manufactured by Biological Industries (Bet Haemek, Israel). Double distilled water only was used in the experiments.

Drug delivery system

The SMEDDS composition is given in Error! Reference source not found. and a detailed description of the formulation development and characteristics is found in (15). Briefly, the combination of polar lipid excipients forms a SMEDDS that provides high solubility (59 mg/g) and stability of ART in both the water-free SMEDDS itself and the corresponding microemulsions (ME) obtained by the addition of H₂O or PBS. SMEDDS-
50 and SMEDDS-20 formulations were prepared from a solution of ART in SMEDDS-100 (or drug-free SMEDSS-100 for placebo) immediately before administration. Specific amounts of PBS were added to give SMEDDS-50 or SMEDDS-20 (Error! Reference source not found.) and the ME was then sterile-filtered through a syringe filter.

**-Table 8-**

**Hemolysis**

A suspension of $8 \times 10^9$ human red blood cells/ml was prepared in PBS. Examined formulations were added in 500 µl to the equal volume of cell suspension. Triton X served as a positive control (known to cause total hemolysis), whereas saline (0.154 mol/L NaCl) served as negative control. The sample plates were incubated for one hour at 37 ºC, then centrifuged and the optical density of the supernatants was measured at a wavelength of 540 nm using a UV/Vis spectrometer.

**In vivo experiments**

**Animals.** Experiments were carried out in C57Bl/6 Ola-Hsd male mice (from Harlan, Israel) aged 7-8 weeks. For the determination of ART serum concentrations, 10 week old male ICR Harlan-Sprague-Dawley (ICR) mice (from Harlan, Israel) were used instead (so as to obtain increased amounts of serum). Both mouse species succumb to
severe malaria with indications of cerebral damage, following infection with *Plasmodium berghei* ANKA (46).

The mice were housed in groups and maintained under standard conditions, a 12 hour on/off light cycle and unlimited access to food and water. Experiments were performed in accordance with institutional guidelines for animal care, by protocols approved by the Animal Ethical Care Committee of The Hebrew University of Jerusalem (Protocol No. MD-12-1351; Golenser’s accreditation No. 12180)

**Infection of animals.** The strain of *Plasmodium berghei* ANKA (PbA MRA-311, CDC Atlanta) used in the experiments was maintained by serial transfer of parasitized erythrocytes (PE) from infected to naïve mice. Experimental mice were infected by i.p. injections of $5 \times 10^4$ PE from peripheral blood of infected passage mice, which caused fatal severe malaria with cerebral involvement on day 6-10 post-infection (p.i.) in at least 90 % of the infected animals.

**Monitoring of infection.** Thin blood smears from tail blood were prepared every two to three days to monitor parasitemia in the infected mice. They were stained with Giemsa staining-solution, and the number of PE per 10,000 red blood cells was determined via light microscopy. Samples were also assessed for anemia and reticulocytosis.

**Severe malaria mouse model.** This work used C57Bl/6 mice infected with *Plasmodium berghei* ANKA as a model of numerous aspects of severe malaria that manifest in humans. The model is well-established and comprehensively described in (92, 93). Infection and pathology in our animals were confirmed to be in accordance with the...
severe malaria mouse model: untreated mice exhibited a variety of characteristic clinical signs as manifestations of the infection (ranging from a ruffled coat, hunching and apathy to neurological symptoms such as convulsion and coma that are indicative of cerebral malaria). Dying mice were sacrificed 6-9 days p.i. Histology of hematoxylin and eosin-stained organs revealed mild but significant changes of tissues in the liver and spleen and few parasites in the brain (data not shown). Injections of Evans Blue (i.v., 0.2 ml of 1 % w/v in PBS/mouse) led to staining of the brain tissue of infected mice but not naïve mice, demonstrating an effect of the infection to permeabilize the blood-brain barrier. Parasitemia levels in these mice were below 20 %, and animals were categorized as suffering from cerebral malaria (CM).

Some animals in which the course of the disease was altered, e.g. by treatment, exhibited prolonged survival of up to four weeks. They showed gradually increasing signs of severe anemia (colorless eyes, cold skin, rapid weight loss, apathy), while blood smears revealed hyper-parasitemia of 30-70 % PE and reticulocytosis (> 30 % reticulocytes compared to 1-4 % in non-infected mice). The hematocrit in three representative mice was found to be below 25 % as measured by centrifugation of tail vein blood in heparinized capillaries. These animals were consequently classed as succumbing to anemic malaria (AM).

Mice that exhibited no recurrence of parasites in the tail blood smears after treatment until the end of the experiment, at least 28 days p.i. or 21 days post-treatment, were considered as “survived".
**Artemisone serum concentrations**

**Dosing and sample collection.** Male ICR mice weighing about 50 g were fed via gavage with either 40 mg ART/kg bodyweight in 200 µl SMEDDS-20, or 200 µl drug-free formulation. The animals were bled from the eye into Mini collect tubes (0.8 ml Z Serum Sep Clot Activator, Greiner Bio-one, Kremsmünster, Austria) after 2 or 8 hours (artemisone treated) and 2 hours (placebo); with n = 3 in all three groups.

After 60 min, cells were separated from the serum by centrifugation and the serum collected in vials of 100 µl each. Samples were then frozen and lyophilized before being stored at -80 °C until LC-MS analysis.

**LC-MS analysis.** The lyophilized serum was reconstituted in 100 µl bi-distilled water. To each tube 500 µl ethyl ether was added, samples centrifuged and stored at -20 °C for 60 minutes. The supernatant was collected, and the solvent completely evaporated. The residue was then dissolved in a solution of 15 µg/ml indomethacin (internal standard) in ethanol and diluted as necessary before LC-MS analysis.

Artemisone was quantified using HPLC (Agilent/HP 1100 HPLC series, high-pressure pump, degasser and autosampler, now Agilent Technologies, Inc. USA) with a LCQ Finnigan MAT mass spectrometer (Thermo/Finnigan, San Jose, USA) as detector. Experiments were performed on an Eurospher 100-5 C18 100x2 mm column (Knauer, Berlin, Germany). Data were processed with Xcalibur® data acquisition software (Thermo Fisher Scientific, Waltham, USA). The LC-MS method was developed and validated based on ICH guidelines (94) (Table 9) (LLD = 60 ng/ml; LLQ = 180 ng/ml; R² > 0.993). As standards for validation and calibration, mouse serum spiked with different
amounts of ART was lyophilized before being reconstituted and processed identically to the samples collected in the experiment. Indomethacin (15 µg/ml) served as internal standard (95).

-Table 9-

**Treatment**

**Drug administration.** Male, 8-9 weeks old C57Bl/6 mice were randomized into groups after infection. Untreated infected mice served as the control group in all the experiments. The animals were treated once or twice a day, days 3-5 or 6-9 (late rescue) p.i. (see experimental design). The microemulsions were administered either via i.p. injections, gavage or intranasally with a fine pipette. For intranasal administration, the mice were kept on their backs to allow the drug to reach the olfactory region/upper nasal cavity to promote possible “nose-to-brain transport” (45). Drugs were delivered in microemulsion volumes of 200 µl, 25 µl and 100 µl for gavage, intranasal and i.p. treatments, respectively. The PBS content was varied to obtain a viscosity that allowed administration and a sufficient solubility of ART (Error! Reference source not found., Table 10). Drug concentration was adjusted as needed, between 10 and 40 mg/kg based on an average bodyweight of 25 g per mouse, and the respective drug-free microemulsions were administered as placebo. All drug doses given in this article are calculated as mg/kg bodyweight.

-Table 10-
Experimental design. We focused our experiments on different aspects of pharmacokinetics, including the parameters listed below:

(A) Prophylactic treatment, in vivo bioassay complementary to ART serum concentrations

(B) Dose-response

(C) Dosing intervals (once/twice daily)

(D) Impact of the route of application (oral/i.p./intranasal)

(E) Late treatment (during days 6-9 p.i.)

The detailed design of each experiment is presented in the corresponding results section. All experiments were repeated once (except for one indicated variation).

Statistical tests

Chi-square tests were performed using GraphPad Prism.

All other statistical testing was done using IBM® SPSS® Version 25. Kaplan-Meier survival tables, and plots were generated using lifetime as time, death as event (surviving mice were censored) and treatment or application route, respectively, as factor. Factor values were compared using overall log rank (Mantel-Cox) test. The result is statistically significant, when $p \leq 0.05$ ($\alpha = 5.00 \%$), and highly significant, when $p \leq 0.001$ ($\alpha = 0.10 \%$).

Acknowledgements:

We are grateful to Cipla (Mumbai, India) for the donation of artemisone. We thank Prof. Salah Mécheri from Institut Pasteur, Paris, France, for the donation of the *Plasmodium berghei* ANKA. We gratefully acknowledge the help of Dr. Henrike Lucas with the
statistical analysis, Manuela Woigk for her assistance with the HPLC/MS measurements and Dareen Mohammad for her help in monitoring parasitemias.

The work was supported by the Deutsche Forschungsgemeinschaft [DFG grants GR 972/47-2 and MA 1648/12-2]. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
References:

1. WHO Global Malaria Programme. 2015. Guidelines for the treatment of malaria, 3rd edition.

2. Phyo AP, Von Seidlein L. 2017. Challenges to replace ACT as first-line drug. Malar J 16:1–5.

3. Müller O, Lu GY, Von Seidlein L. 2019. Geographic expansion of artemisinin resistance. J Travel Med 26:1–6.

4. Nagelschmitz J, Voith B, Wensing G, Roemer A, Fugmann B, Haynes RK, Kotecka BM, Rieckmann KH, Edstein MD. 2008. First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob Agents Chemother 52:3085–91.

5. Ramharter M, Burkhardt D, Nemeth J, Adegnika AA, Kremsner PG. 2006. Short report: In vitro activity of artemisone compared with artesunate against Plasmodium falciparum. Am J Trop Med Hyg 75:637–639.

6. Haynes RK, Fugmann B, Stetter J, Rieckmann K, Heilmann HD, Chan HW, Cheung MK, Lam WL, Wong HN, Croft SL, Vivas L, Rattray L, Stewart L, Peters W, Robinson BL, Edstein MD, Kotecka B, Kyle DE, Beckermann B, Gerisch M, Radtke M, Schmuck G, Steinke W, Wollborn U, Schmeer K, Römer A. 2006. Artemisone - A highly active antimalarial drug of the artemisinin class. Angew Chemie - Int Ed 45:2082–2088.
7. Wknine-Grinberg JH, Hunt N, Bentura-Marciano A, McQuillan JA, Chan HW, Chan WC, Barenholz Y, Haynes RK, Golenser J. 2010. Artemisone effective against murine cerebral malaria. Malar J 9:1–15.

8. Zech J, Gold D, Salaymeh N, Sasson NC, Rabinowitch I, Golenser J, Mäder K. 2020. Oral administration of artemisone for the treatment of schistosomiasis: Formulation challenges and in vivo efficacy. Pharmaceutics 12:1–5.

9. Oiknine-Djian E, Bar-On S, Laskov I, Lantsberg D, Haynes RK, Panet A, Wolf DG. 2019. Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. Antiviral Res 172:104639.

10. Vivas L, Rattray L, Stewart LB, Robinson BL, Fugmann B, Haynes RK, Peters W, Croft SL. 2007. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J Antimicrob Chemother 59:658–665.

11. Siriwardana A, Iyengar K, Roepe PD. 2016. Endoperoxide Drug Cross-Resistance Patterns for Plasmodium falciparum Exhibiting an Artemisinin Delayed-Clearance Phenotype Downloaded from. Antimicrob Agents Chemother 60:6952–6956.

12. Lanteri CA, Chorattanakawee S, Lon C, Saunders DL, Rutvisutthinunt W, Yingyuen K, Bathurst I, Ding XC, Tyner SD. 2014. Ex Vivo Activity of Endoperoxide Antimalarials, Including Artemisone and Arterolane, against Multidrug-Resistant Plasmodium falciparum Isolates from Cambodia. Antimicrob Agents Chemother 58:5831–5840.
13. Golenser J, Buchholz V, Bagheri A, Nasereddin A, Dzikowski R, Guo J, Hunt NH, Eyal S, Vakruk N, Greiner A. 2017. Controlled release of artemisone for the treatment of experimental cerebral malaria. Parasites and Vectors. https://doi.org/10.1186/s13071-017-2018-7.

14. Golenser J, Salaymeh N, Higazi AA, Alyan M, Daif M, Dzikowski R, Domb AJ, Miranda AS. 2020. Treatment of Experimental Cerebral Malaria by Slow Release of Artemisone From Injectable Pasty Formulation. Front Pharmacol 11.

15. Zech J, Gold D, Salaymeh N, Sasson NC, Rabinowitch I, Golenser J, Mäder K. 2020. Oral administration of artemisone for the treatment of schistosomiasis: Formulation challenges and in vivo efficacy. Pharmaceutics 12:1–17.

16. Saeed MEM, Krishna S, Greten HJ, Kremsner PG, Efferth T. 2016. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol Res 110:216–226.

17. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1994. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharm Res 12:413–420.

18. Steyn JD, Wiesner L, du Plessis LH, Grobler AF, Smith PJ, Chan W-CC, Haynes RK, Kotzé AF. 2011. Absorption of the novel artemisinin derivatives artemisone and artemiside: Potential application of PheroidTM technology. Int J Pharm 414:260–266.

19. Gold D, Alian M, Domb A, Karawani Y, Jbarien M, Chollet J, Haynes RK, Wong HN, Buchholz V, Greiner A, Golenser J. 2017. Elimination of Schistosoma
mansoni in infected mice by slow release of artemisone. Int J Parasitol Drugs Drug Resist 7:241–247.

20. Burger C. 2018. Natural oil nano-emulsion dispersions for the topical delivery of clofazimine, artemisone and decoquinate. North-West University, South Africa.

21. van Zyl L, Viljoen JM, Haynes RK, Aucamp M, Ngwane AH, du Plessis J. 2019. Topical Delivery of Artemisone, Clofazimine and Decoquinate Encapsulated in Vesicles and Their In vitro Efficacy Against Mycobacterium tuberculosis. AAPS PharmSciTech 20:1–11.

22. Dwivedi A, Mazumder A, Fox LT, Brümmer A, Gerber M, Du Preez JL, Haynes RK, Du Plessis J. 2016. In vitro skin permeation of artemisone and its nano-vesicular formulations. Int J Pharm 503:1–7.

23. Dwivedi A, Mazumder A, du Plessis L, du Preez JL, Haynes RK, du Plessis J. 2015. In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. Nanomedicine Nanotechnology, Biol Med 11:2041–2050.

24. Zech J, Timoracky M, Syrowatka F, Mäder K. 2018. Artemisone in Electrosprayed Solid Lipid Microparticles, p. 1–2. In PBP World Meeting, Granada, Spain.

25. Hattingh S. 2018. Development of lipid matrix tablets containing a double fixed dose combination of artemisone and lumefantrine. North-West University, South Africa.

26. Bagheri AR, Agarwal S, Golenser J, Greiner A. 2017. Unlocking Nanocarriers for the Programmed Release of Antimalarial Drugs. Glob Challenges 1:1600011.
27. Duan G, Bagheri AR, Jiang S, Golenser J, Agarwal S, Greiner A. 2017. Exploration of Macroporous Polymeric Sponges As Drug Carriers. Biomacromolecules 18:3215–3221.

28. Craig AG, Grau GE, Janse C, Kazura JW, Milner D, Barnwell JW, Turner G, Langhorne J. 2012. The role of animal models for research on severe malaria. PLoS Pathog 8.

29. Hunt NH, Grau GE, Engwerda C, Barnum SR, van der Heyde H, Hansen DS, Schofield L, Golenser J. 2010. Murine cerebral malaria: the whole story. Trends Parasitol 26:271–272.

30. Sarr D, Yai J, Doritchamou A, John A, Luty F, Moore JM, Marinho CRF, Barateiro A, Pereira MLM, Epiphanio S. 2019. Contribution of Murine Models to the Study of Malaria During Pregnancy. Front Microbiol | www.frontiersin.org 10.1369.

31. WHO. 2014. Severe malaria. Trop Med Int Heal 19:7–131.

32. Gomes MF, Faiz MA, Gyapong JO, Warsame M, Agbenyega T, Babiker A, Baiden F, Yunus EB, Binka F, Clerc C, Folb P, Hassan R, Hossain MA, Kimbute O, Kitua A, Krishna S, Makasi C, Mensah N, Mrango Z, Olliaro P, Peto R, Peto TJ, Rahman MR, Ribeiro I, Samad R, White NJ. 2009. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 373:557–566.

33. WHO Global Malaria Programme. 2017. Rectal artesunate for pre-referral treatment of severe malaria.
34. Slomkowski S, Alemán J V., Gilbert RG, Hess M, Horie K, Jones RG, Kubisa P, Meisel I, Mormann W, Penczek S, Stepto RFT. 2011. Terminology of polymers and polymerization processes in dispersed systems (IUPAC recommendations 2011). Pure Appl Chem 83:2229–2259.

35. Schulman JH, Stoeckenius W, Prince LM. 1959. Mechanism of formation and structure of micro emulsions by electron microscopy. J Phys Chem 63:1677–1680.

36. Constantinides PP. 1995. Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects. Pharm Res 12:1561–1572.

37. Gibaud S, Attivi D. 2012. Microemulsions for oral administration and their therapeutic applications. Expert Opin Drug Deliv 9:937–951.

38. Novartis. 2009. Prescribing Information NEORAL® Soft Gelatin Capsules. Novartis Pharmaceuticals Corporation.

39. AbbVie Inc. 2017. Prescribing Information NORVIR®. AbbVie Inc.

40. Tayade NG, Nagarsenker MS. 2010. Development and evaluation of artemether parenteral microemulsion. Indian J Pharm Sci 72:637–640.

41. Joshi M, Pathak S, Sharma S, Patravale V. 2008. Solid microemulsion preconcentrate (NanoSorb) of artemether for effective treatment of malaria. Int J Pharm 362:172–178.

42. Patil S, Suryavanshi S, Pathak S, Sharma S, Patravale V. 2013. Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria.
Mandawgade SD, Sharma S, Pathak S, Patravale VB. 2008. Development of SMEDDS using natural lipophile: Application to β-Artemether delivery. Int J Pharm 362:179–183.

Bhandari S, Bhandari V, Sood J, Jaswal S, Rana V, Bedi N, Sehgal R, Tiwary AK. 2017. Improved pharmacokinetic and pharmacodynamic attributes of artemether–lumefantrine-loaded solid SMEDDS for oral administration. J Pharm Pharmacol 69:1437–1446.

Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. 2018. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 143:155–170.

Touitou E, Waknine JH, Godin B, Golenser J. 2006. Treatment of malaria in a mouse model by intranasal drug administration. Int J Parasitol 36:1493–1498.

Marijon A, Bonnot G, Fourier A, Bringer C, Lavoignat A, Gagnieu M, Bienvenu A, Picot S. 2014. Efficacy of intranasal administration of artesunate in experimental cerebral malaria. Malar J 13:1–10.

Kay K, Hodel EM, Hastings IM. 2015. Altering antimalarial drug regimens may dramatically enhance and restore drug effectiveness. Antimicrob Agents Chemother 59:6419–6427.

Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, Tilley L. 2013. Altered temporal response of malaria parasites determines differential
sensitivity to artemisinin. Proc Natl Acad Sci U S A 110:5157–5162.

50. White NJ. 2017. Malaria parasite clearance. Malar J 16:1–14.

51. White NJ. 1997. Assessment of the pharmacodynamic properties of antimalarial
drugs in vivo. Antimicrob Agents Chemother 41:1413–1422.

52. Saralamba S, Pan-Ngum W, Maude RJ, Lee SJ, Tarning J, Lindegårdh N, Chotivanich K, Nosten F, Day NPJ, Socheat D, White NJ, Dondorp AM, White LJ. 2011. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 108:397–402.

53. Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. 2016. Artemisinin Action and Resistance in Plasmodium falciparum. Trends Parasitol 32:682–696.

54. WHO Global Malaria Programme. 2018. Status report on artemisinin resistance and ACT efficacy.

55. Pennington AK, Ratcliffe JH, Wilson CG, Hardy JG. 1988. The influence of solution viscosity on nasal spray deposition and clearance. Int J Pharm 43:221–224.

56. Ali J, Ali M, Baboota S, Kaur Sahni J, Ramassamy C, Dao L, Bhavna. 2010. Potential of Nanoparticulate Drug Delivery Systems by Intranasal Administration. Curr Pharm Des 16:1644–1653.

57. Pires A, Fortuna A, Alves G, Falcão A. 2009. Intranasal drug delivery: How, why and what for? J Pharm Pharm Sci 12:288–311.

58. Bshara H, Osman R, Mansour S, El-Shamy AEHA. 2014. Chitosan and
cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats. Carbohydr Polym 99:297–305.

59. Elshafeey AH, Bendas ER, Mohamed OH. 2009. Intranasal Microemulsion of Sildenafil Citrate: In Vitro Evaluation and In Vivo Pharmacokinetic Study in Rabbits. AAPS PharmSciTech 10:361–367.

60. Ghazanfari N, Mueller SN, Heath WR. 2018. Cerebral malaria in mouse and man. Front Immunol 9:1–11.

61. Wknine-Grinberg JH, Even-Chen S, Avichzer J, Turjeman K, Bentura-Marciano A, Haynes RK, Weiss L, Allon N, Ovadia H, Golenser J, Barenholz Y. 2013. Glucocorticosteroids in Nano-StERICALLY Stabilized Liposomes Are Efficacious for Elimination of the Acute Symptoms of Experimental Cerebral Malaria. PLoS One 8.

62. Lawrence MJ, Rees GD. 2012. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 64:175–193.

63. Hunt NH, Manduci N, Thumwood CM. 1993. Amelioration of murine cerebral malaria by dietary restriction. Parasitology 107:471–476.

64. Zhang P, Liu Y, Feng N, Xu J. 2008. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm 355:269–276.

65. Xiao Y, Chen X, Yang L, Zhu X, Zou L, Meng F, Ping Q. 2013. Preparation and oral bioavailability study of curcuminoid-loaded microemulsion. J Agric Food Chem 61:3654–3660.
66. Das D, Tripura R, Phyo AP, Lwin KM, Tarning J, Lee SJ, Hanpithakpong W, Stepniewska K, Menard D, Ringwald P, Silamut K, Imwong M, Chotivanich K, Yi P, Day NPJ, Lindegardh N, Socheat D, Nguon C, White NJ, Nosten F, Dondorp AM. 2013. Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis 56:48–58.

67. Kremsner PG, Adegnika AA, Hounkpatin AB, Zinsou JF, Taylor TE, Chimalizeni Y, Liomba A, Kombila M, Bouyou-Akotet MK, Mawili Mboumba DP, Agbenyega T, Ansong D, Sylverken J, Ogutu BR, Otieno GA, Wangwe A, Bojang KA, Okomo U, Sanya-Isijola F, Newton CR, Njungu P, Kazungu M, Kerb R, Geditz M, Schwab M, Velavan TP, Nguetse C, Köhler C, Issifou S, Bolte S, Englertner T, Mordmüller B, Krishna S. 2016. Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial. PLoS Med 13:1–22.

68. Jones S, Hodel EM, Sharma R, Kay K, Hastings IM. 2019. Optimal treatments for severe malaria and the threat posed by artemisinin resistance. J Infect Dis 219:1243–1253.

69. Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, Tilley L. 2013. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci U S A 110:5157–5162.

70. Le Manach C, Scheurer C, Sax S, Schleiferböck S, Cabrera DG, Younis Y, Paquet T, Street L, Smith P, Ding XC, Waterson D, Witty MJ, Leroy D, Chibale K, Wittlin S. 2013. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malar J 12:1–7.
71. Murithi JM, Owen ES, Istvan ES, Lee MCS, Ottilie S, Chibale K, Goldberg DE, Winzeler EA, Llinás M, Fidock DA, Vanaerschot M. 2020. Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery. Cell Chem Biol 27:158-171.e3.

72. Vyas N, Avery BA, Avery MA, Wyandt CM. 2002. Carrier-mediated partitioning of artemisinin into plasmodium falciparum-infected erythrocytes. Antimicrob Agents Chemother 46:105–109.

73. Hastings IM, Kay K, Hodel EM. 2015. How robust are malaria parasite clearance rates as indicators of drug effectiveness and resistance? Antimicrob Agents Chemother 59:6428–6436.

74. Kremsner PG, Taylor T, Issifou S, Kombila M, Chimalizeni Y, Kawaza K, Bouyou Akotet MK, Duscha M, Mordmüller B, Kösters K, Humberg A, Miller RS, Weina P, Duparc S, Möhrle J, Kun JFJ, Planche T, Teja-Isavadharm P, Simpson JA, Köhler C, Krishna S. 2012. A simplified intravenous artesunate regimen for severe malaria. J Infect Dis 205:312–319.

75. Aghazadeh-Habashi A, Ibrahim A, Carran J, Anastassiades T, Jamali F. 2006. Single dose pharmacokinetics and bioavailability of butyryl glucosamine in the rat. J Pharm Pharm Sci 9:359–364.

76. Espinoza LC, Vacacela M, Clares B, Garcia ML, Fabrega MJ, Calpena AC. 2018. Development of a Nasal Donepezil-loaded Microemulsion for Treatment of Alzheimer’s Disease: in vitro and ex vivo Characterization. CNS Neurol Disord Drug Targets 17:43–53.
77. Grubb BR, Jones JH, Boucher RC. 2004. Mucociliary transport determined by in vivo microdialysis in the airways of normal and CF mice. Am J Physiol - Lung Cell Mol Physiol 286:588–595.

78. Thakkar HP, Patel AA, Chauhan NP. 2013. Intranasal mucoadhesive microemulsion of mirtazapine: Pharmacokinetic and pharmacodynamic studies. Asian J Pharm 7:36–42.

79. Patel RB, Patel MR, Bhatt KK, Patel BG, Gaikwad R V. 2016. Evaluation of brain targeting efficiency of intranasal microemulsion containing olanzapine: Pharmacodynamic and pharmacokinetic consideration. Drug Deliv 23:307–315.

80. Shah B, Khunt D, Misra M, Padh H. 2018. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting. Pharm Res 35.

81. Yao J, Hou L, Zhou JP, Zhang ZQ, Sun L. 2009. Preparation of lorazepam-loaded microemulsions for intranasal delivery and its pharmacokinetics. Pharmazie 64:642–647.

82. Patel MR, Patel RB, Bhatt KK, Patel BG, Gaikwad R V. 2016. Paliperidone microemulsion for nose-to-brain targeted drug delivery system: Pharmacodynamic and pharmacokinetic evaluation. Drug Deliv 23:346–354.

83. Lalani J, Baradia D, Lalani R, Misra A. 2015. Brain targeted intranasal delivery of tramadol: Comparative study of microemulsion and nanoemulsion. Pharm Dev Technol 20:992–1001.
84. Gizurarson S. 1993. The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev 11:329–347.

85. Vyas TK, Babbar AK, Sharma RK, Misra A. 2005. Intranasal mucoadhesive microemulsions of zolmitriptan: Preliminary studies on brain-targeting. J Drug Target 13:317–324.

86. Amante FH, Haque A, Stanley AC, Rivera F de L, Randall LM, Wilson YA, Yeo G, Pieper C, Crabb BS, de Koning-Ward TF, Lundie RJ, Good MF, Pinzon-Charry A, Pearson MS, Duke MG, McManus DP, Loukas A, Hill GR, Engwerda CR. 2010. Immune-Mediated Mechanisms of Parasite Tissue Sequestration during Experimental Cerebral Malaria. J Immunol 185:3632–3642.

87. Strauss WL, Layton ME, Dager SR. 1998. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry 155:380–384.

88. Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter CH, Zöchling R, Boissl KW, Leblhuber F, Riederer P. 1999. Persistence of haloperidol in human brain tissue. Am J Psychiatry 156:885–890.

89. Jain K, Sood S, Gowthamarajan K. 2015. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv 22:940–954.

90. Bshara H, Osman R, Mansour S, El-Shamy AEHA. 2014. Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats. Carbohydr Polym 99:297–305.
944  91. Southam DS, Dolovich M, O’byrne PM. 2002. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 282:833–839.

947  92. Hunt N, Grau GE. 2003. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol 24:491-499.

949  93. Oca MM De, Engwerda C, Haque A. 2013. Mouse Models of Innate Immunity: Methods and Protocols Methods in Molecular Biology. Humana Press.

951  94. Use IC for H of TR for P for H. 2005. VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGYQ2(R1).

953  95. Gu Y, Li Q, Melendez V, Weina P. 2008. Comparison of HPLC with electrochemical detection and LC-MS/MS for the separation and validation of artesunate and dihydroartemisinin in animal and human plasma. J Chromatogr B Anal Technol Biomed Life Sci 867:213–218.
Fig 1: Prophylactic treatment: Parasitemias of mice treated once with ART 40 mg/kg bodyweight in 200 µl SMEDDS-20 via gavage 0.5, 2 or 24 h prior to infection with *P. berghei* ANKA. The number of animals succumbing to either cerebral malaria (CM) or anemic malaria (AM) is given for each group.
Figure 2: Dose-response study in infected mice: parasitemia in mice that were treated with 10 – 40 mg ART/ kg bodyweight via gavage every 24 h on day 3-5 p.i.; the red dot indicates the earliest detection of parasites in the bloodstream.
Figure 3: The effect of different dosing interval on survival of mice treated by gavage on days 3-5 p.i. with (a) 20 mg ART/kg bodyweight every 24 h in 200 µl SMEDDS-20, n = 6; (b) 10 mg ART/kg every 12 h in 100 µl SMEDDS-20, n = 5; Control mice, n=8. The significance of the influence of the treatment on the survival of the mice was tested using SPSS®. Based on the log rank test data, the treatment regime had a highly significant influence on the survival (p < 0.001).
Figure 4: The effect of the route of application on mouse survival.

Mice were treated with 20 mg ART/ kg bodyweight on days 3-5 p.i., every 24 h by

(a) gavage, n = 6; (b) i.p. injection, n = 6; (c) intranasal administration, n = 6; Control mice, n = 8. A significant influence of the application route on the survival of the mice was tested using SPSS®. Based on the log rank test data, the application route had a highly significant influence on the survival (p < 0.001).
Table 1: Published drug delivery systems for Artemisone

| Drug delivery system                                      | Route of administration | *Applied or suggested potential application | Reference |
|-----------------------------------------------------------|-------------------------|---------------------------------------------|------------|
| Nanoemulsion                                              | Topical                 | Cutaneous tuberculosis *In vitro             | (20)       |
| Nano-vesicular formulations (liposomes, transferosomes, niosomes, PheroidTM system*) | Topical                 | Cutaneous tuberculosis *In vitro             | (21)       |
| Solid lipid nanoparticles                                 | Topical                 | **Melanoma *Melanoma In vitro               | (22, 23)   |
| Solid lipid microparticles                                | Oral*                   | **Malaria                                   | (18)       |
| SMEDDS/ microemulsion                                     | Oral                    | **Malaria                                   | (24)       |
| Solid polymer implants                                     | S.c. implantation       | *Malaria In mice                            | (13)       |
| Injectable pasty polymer implants (poly (sebacic acid–ricinoleic acid) gel) | S.c. injection          | *Malaria In mice                            | (14)       |
| Solid polymer implants                                     | S.c. implantation       | *Schistosomiasis In mice                    | (19)       |
| Lipid matrix tablet                                       | Oral                    | **Malaria                                   | (25)       |
| Electrospun nanofibers                                    | Infusion (ex vivo extraction) | **Malaria                                 | (26)       |
| Macro-porous polymeric sponges                            | Implantation / Infusion (ex vivo extraction) | **Malaria                                 | (27)       |
Table 2: ART serum concentrations found in mice (n=3 per time point) 2 and 8 hours after treatment with either placebo or 40 mg/kg bodyweight ART by gavage.

| time post administration | administered formulation | ART serum (µg/ml) |
|--------------------------|--------------------------|------------------|
| 2 h                      | placebo                  | 0 | 0 | 0     |
|                          | ART 40mg/kg              | 0.9 | 2.3 | 1.3 |
| 8 h                      | ART 40mg/kg              | 0.6 | < LLQ* | < LLQ* |

*LLQ = lower limit of quantification = 0.18 µg/ml
Table 3: Day of death from severe malaria of mice treated with drug-free SMEDDS (parasitemia in all mice were below 15% throughout the experiment).

| treatment group | administered formulation | day of death (day p.i.) |
|-----------------|--------------------------|-------------------------|
| control         | -                        | 8 | 8 | 8 | 8 | 8 | 9              |
| oral (gavage)   | SMEDDS-20                | 8 | 8 | 8 | 9              |
|                 | 200 µl                   |             |
| Intranasal      | SMEDDS-50                | 7 | 7 | 7 | 7 | 7              |
|                 | 20 µl                    |             |
Table 4: Dose-response study in infected mice. The mice were treated with 10 – 40 mg ART/kg bodyweight by gavage every 24 h on days 3-5 p.i. Combined results of two identical experiments are presented as number of deaths due to cerebral malaria (CM) or anemic malaria (AM), and parasite-free survival.

| treatment group | CM | AM | survived |
|-----------------|----|----|----------|
| Control (n = 9) | 9  | -  | -        |
| 10 mg ART/kg    | 5  | 4  | -        |
| (n = 9)         |    |    |          |
| 20 mg ART/kg    | 4  | 4  | 2        |
| (n = 10)        |    |    |          |
| 40 mg ART/kg    | 3  | 4  | 3        |
| (n = 10)        |    |    |          |
Table 5: Dosing interval study in infected mice. Combined results of two identical experiments are presented. Mice were treated by gavage on days 3-5 p.i. with (a) 20 mg ART/kg bodyweight every 24 h in 200 µl SMEDDS-20; (b) 10 mg ART/kg every 12 h in 100 µl SMEDDS-20. Results are presented as number of deaths due to cerebral malaria (CM) or anemic malaria (AM), and parasite-free survival.

| treatment group       | CM | AM | survived |
|-----------------------|----|----|----------|
| control (n = 8)       | 7  | 1  | -        |
| 10 mg ART/kg every 12 h (n = 7) | -  | -  | 7        |
| 20 mg ART/kg every 24 h (n = 10) | -  | 9  | 1        |
Table 6: The effect of the route of application on infection outcome. Combined results of two identical experiments are presented. Mice were treated with 20 mg ART/kg bodyweight every 24 h on days 3-5 p.i. by gavage / i.p. injection / intranasally. Results are given as deaths due to cerebral malaria (CM) or anemic malaria (AM), and parasite-free survival.

| treatment group | CM | AM | survived |
|-----------------|----|----|----------|
| control (n = 8) | 7  | 1  | -        |
| oral (gavage) (n = 10) | -  | 9  | 1        |
| intranasal (n = 8) | -  | 4  | 4        |
| i.p. (n = 10)    | 3  | 7  | -        |
Table 7: The effect of late treatment on infected mice dosed every 12 h on days 6-9 p.i. with either 20 mg ART/kg bodyweight intranasally or 40 mg ART/kg via gavage. Combined results of two experiments are shown as deaths due to cerebral malaria (AM) or anemic malaria (AM), and parasite-free survival.

| treatment group       | CM | AM | Survived |
|-----------------------|----|----|----------|
| control (n =9)        | 8  | 1  | -        |
| 40 mg ART / kg oral (gavage) (n = 9) | 3  | -  | 6        |
| 20 mg ART / kg intranasal (n =10 ) | 3  | -  | 7        |
Table 8: Composition and properties of the water-free SMEDDS-100 and the microemulsions SMEDDS-50 and SMEDDS-20 derived from it, as used in this work. The image demonstrates the transparency of the three formulations and the opalescence observed for SMEDDS-20.

| SMEDDS-100     | SMEDDS-50 | SMEDDS-20 |
|----------------|-----------|-----------|
| **Composition (wt. %)** | **Composition (wt. %)** |          |
| Kolliphor HS15     | 50        | 20        |
| Propylene glycol  | 10        |           |
| Polysorb ID 46    | 20        |           |
| Capmul MCM        | 20        |           |
|                 | **Particle size (nm)** |          |
|                 | z-average*, 25 °C     | 28        | 86        |
|                 | Kinematic viscosity (mPas), 25 °C | 118    | 10        |
|                 | **Microstructure**    | Bicontineous | O/W      |
|                 | as suggested by Electron microscopy |

*dynamic light scattering, intensity diameter distribution
**Table 9**: LC-MS parameters for quantitative analysis of artemisone in mouse serum.

|                | LC                  | MS                      |
|----------------|---------------------|-------------------------|
| **Mobile phase** | V/V/V               | Ionization              |
|                | ACN 55              | Electrospray ionization (ESI) |
|                | H₂O 45              | Positive-ion mode       |
|                | FA* 0.1             | Single-ion mode         |
| **Flow rate**  | 0.3 ml/min          | m/z = 401.5-403.5 Artemisone (M+1) |
|                |                     |                        |
| **Sample injection volume** | 10 µl         | m/z = 357.8-359.8 Indomethacin (M+1) |
| **Column temperature** | 35 °C              |                         |
| **Retention time** | 5.5 min Indomethacin |                         |
|                | 7.0 min ART         |                         |

*FA: formic acid*
Table 10: Amounts of specific SMEDDS used in treatment experiments depending on the route of application

| route of application | formulation | volume* (µl) |
|----------------------|-------------|--------------|
| oral                 | SMEDDS-20   | 200          |
| nasal                | SMEDDS-50   | 25           |
| i.p.                 | SMEDDS-20   | 100          |

*unless stated otherwise